HbA1c levels for dental implants are a critical consideration for anyone with diabetes planning this treatment. HbA1c — a blood test measuring average glucose control over two to three months — helps clinicians assess whether your body is ready to heal safely after implant surgery. In the UK, poorly controlled blood sugar is linked to impaired wound healing, higher infection risk, and reduced implant success rates. This article explains the HbA1c thresholds used in UK clinical practice, how diabetes affects osseointegration, and what steps you can take to optimise your blood glucose before and after dental implant treatment.

Why HbA1c Levels Matter for Dental Implant Treatment

HbA1c reflects two to three months of average blood glucose and is a key marker for assessing diabetic patients' suitability for implant surgery, as elevated levels impair healing, increase infection risk, and compromise osseointegration.

Dental implants are a long-term restorative solution for missing teeth, but their success depends heavily on the body's ability to heal and integrate the titanium implant with the surrounding jawbone — a process known as osseointegration. For patients living with diabetes, blood glucose control plays a central role in determining whether this process proceeds safely and effectively.

HbA1c (glycated haemoglobin) is a blood test that reflects average blood glucose levels over the preceding two to three months. In the UK, it is expressed in millimoles per mole (mmol/mol) in line with IFCC standardisation adopted by the NHS, though percentage values are sometimes shown alongside for reference. Because it provides a longer-term picture of glycaemic control — rather than a single-point reading — HbA1c is a key marker used alongside other clinical factors when assessing a diabetic patient's suitability for elective surgical procedures, including dental implants.

It is worth noting that NICE sets different HbA1c targets depending on the type of diabetes: for adults with type 2 diabetes, the general target is 53 mmol/mol (7.0%) or below (NICE NG28), whilst for adults with type 1 diabetes, the recommended target is 48 mmol/mol (6.5%) or below where safely achievable (NICE NG17). These are glycaemic management targets and do not in themselves constitute mandated surgical thresholds, but they provide a useful clinical reference point.

Elevated HbA1c levels are associated with impaired immune function, reduced wound healing capacity, and increased susceptibility to infection. All of these factors are directly relevant to implant surgery, which involves incisions in the gum tissue, drilling into the jawbone, and a healing period that can last several months. Understanding your HbA1c level before proceeding with implant treatment is therefore not merely a formality — it is a clinically important step that can significantly influence the outcome of your procedure.

Recommended HbA1c Thresholds Before Implant Surgery in the UK

There is no single UK-mandated cut-off, but ≤53 mmol/mol (7.0%) is widely considered acceptable; levels ≥69 mmol/mol (8.5%) generally prompt deferral until glycaemic control improves.

There is no single UK-mandated HbA1c cut-off for dental implant surgery. Guidance from professional bodies such as the College of General Dentistry (CGDent) and the Faculty of General Dental Practice (FGDP) frames diabetes as a modifiable risk factor requiring individualised assessment rather than a fixed numerical threshold. Peri-operative guidance from the Centre for Perioperative Care (CPOC) similarly emphasises risk-based, individualised decision-making. Thresholds cited in the dental and surgical literature should therefore be understood as clinical reference points, not absolute rules.

With that context, the most widely referenced benchmark in the implant literature is an HbA1c of 53 mmol/mol (7.0%) or below, which aligns with NICE's type 2 diabetes management target (NG28). Many implant surgeons and oral and maxillofacial specialists use this figure as a starting point for assessing suitability.

Some clinicians may consider implant treatment in patients with HbA1c levels up to 59–64 mmol/mol (7.5–8.0%), provided other risk factors are carefully managed and the patient is under close medical supervision. However, levels above 69 mmol/mol (8.5%) are generally considered to represent poorly controlled diabetes, and most UK specialists would advise deferring elective implant surgery until glycaemic control improves.

Key reference points used in clinical practice:

• ≤53 mmol/mol (7.0%): Generally considered acceptable for implant surgery

• 54–64 mmol/mol (approximately 7.1–8.0%): Borderline; requires case-by-case clinical judgement and careful risk assessment

• ≥69 mmol/mol (8.5%): Elective implant surgery is usually deferred until glycaemic control improves

For patients with type 1 diabetes, the NICE-recommended HbA1c target of 48 mmol/mol (6.5%) (NG17) provides an additional reference, though the same principle of individualised risk assessment applies.

HbA1c is just one component of the pre-operative assessment. Factors such as the type and duration of diabetes, presence of complications, smoking status, oral hygiene, and overall medical history are all considered alongside glycaemic control when determining suitability for treatment.

How Poorly Controlled Diabetes Affects Implant Success Rates

Poorly controlled diabetes increases rates of peri-implantitis, delayed healing, and early implant loss by impairing wound healing, neutrophil function, osteoblast activity, and microvascular blood supply.

The relationship between diabetes and dental implant outcomes has been studied extensively. Well-controlled diabetes is not considered an absolute contraindication to implant treatment, but poorly controlled diabetes is associated with a measurably higher risk of complications and implant failure.

From a physiological standpoint, chronic hyperglycaemia impairs several processes that are essential for successful osseointegration:

• Impaired wound healing: High blood glucose reduces collagen synthesis and slows the proliferation of fibroblasts, the cells responsible for tissue repair.

• Increased infection risk: Hyperglycaemia compromises neutrophil function and reduces the body's ability to fight bacterial infection at the surgical site.

• Altered bone metabolism: Diabetes can reduce osteoblast activity and increase osteoclast-mediated bone resorption, weakening the bone-implant interface.

• Microvascular changes: Long-standing diabetes affects small blood vessels, reducing blood supply to healing tissues.

Clinical research, including systematic reviews and meta-analyses published in journals such as the Journal of Clinical Periodontology, suggests that patients with poorly controlled diabetes experience higher rates of peri-implantitis (infection and bone loss around the implant), delayed healing, and early implant loss compared with non-diabetic patients or those with well-managed blood glucose. It should be noted that the evidence base is heterogeneous — studies vary in their definitions of glycaemic control, peri-implantitis, and follow-up duration, and confounding factors such as smoking, pre-existing periodontitis, and maintenance compliance can influence outcomes. The BSP/EFP consensus documents on the bidirectional relationship between periodontitis and diabetes further support the view that poor glycaemic control increases peri-implant disease risk.

These findings reinforce the importance of achieving optimal HbA1c levels before surgery — not only to improve the likelihood of implant success, but also to reduce the risk of post-operative complications that could affect overall health.

Working With Your GP and Dentist to Optimise Blood Sugar Control

Collaborate with your GP or diabetes team to improve HbA1c before surgery; inform them of planned procedures, particularly if taking SGLT2 inhibitors, which require specific peri-operative management.

If your HbA1c level is above the threshold at which your clinical team is comfortable proceeding with dental implant surgery, the most important step is to work collaboratively with your GP or diabetes care team to improve glycaemic control before treatment. This process typically takes several months, and it is advisable to begin this conversation well in advance of your planned implant treatment.

Your GP may review your current diabetes medication, dietary habits, and physical activity levels. In some cases, adjustments to your treatment regimen may be recommended. Important: do not alter your diabetes medicines without clinical advice. In particular, some diabetes medications — notably SGLT2 inhibitors (such as dapagliflozin, empagliflozin, and canagliflozin) — may require a specific peri-operative management plan to reduce the risk of a rare but serious complication called euglycaemic diabetic ketoacidosis (DKA). Your GP or diabetes team should be made aware of any planned surgical procedure so they can advise accordingly, in line with CPOC and MHRA guidance. NICE guidance (NG28 for type 2 diabetes; NG17 for type 1 diabetes) supports a structured, individualised approach to diabetes management, and your care team can refer you to a diabetes specialist nurse or dietitian if additional support is needed. NHS-endorsed structured education programmes such as DESMOND (for type 2 diabetes) and DAFNE (for type 1 diabetes) may also be beneficial. NHS Stop Smoking services are available if smoking cessation is relevant to your situation.

From the dental side, your implant dentist or oral surgeon plays an equally important role:

• They should request a recent HbA1c result (ideally within the past three months) as part of your pre-operative assessment.

• They can liaise with your GP or diabetes team to share relevant clinical information.

• They may recommend a course of professional periodontal treatment before implant placement, as gum disease and poor glycaemic control have a bidirectional relationship — each can worsen the other.

Open communication between your dental and medical teams is essential. If you are unsure whether your blood sugar is well enough controlled for implant surgery, ask your GP for an up-to-date HbA1c test and share the result with your dentist. Do not proceed with implant surgery without ensuring both teams are informed and in agreement about your readiness.

What to Expect During the Implant Assessment Process

Pre-implant assessment for diabetic patients includes medical history review, oral health examination, and a point-of-care blood glucose check on the day, with a target range of 6–10 mmol/L before proceeding.

For patients with diabetes, the pre-implant assessment is typically more detailed than for non-diabetic patients. Understanding what this process involves can help you prepare effectively and ensure that all relevant information is available to your clinical team.

The assessment will usually include:

• Medical history review: Your dentist will ask about the type and duration of your diabetes, current medications, any diabetes-related complications (such as neuropathy, retinopathy, or nephropathy), and your most recent HbA1c result.

• Oral health examination: A thorough assessment of your gum health, bone density (often via dental X-rays or, where clinically indicated, a CBCT scan in line with ALARA radiation principles), and overall oral hygiene will be carried out. Active gum disease must be treated before implant placement.

• Blood glucose on the day of surgery: Many clinicians will check a point-of-care capillary blood glucose reading on the day of the procedure before proceeding. In line with CPOC guidance for minor procedures, an acceptable range is generally 6–10 mmol/L, with values between 4–12 mmol/L considered manageable in most cases. If your reading is markedly elevated (for example, above 13–15 mmol/L) or you are feeling unwell, your clinical team may advise postponing the procedure and seeking medical review.

• Discussion of risks and consent: You will be informed of the specific risks associated with implant surgery in the context of your diabetes, and asked to provide informed consent.

For practical preparation, it is generally advisable to:

• Schedule your appointment in the morning where possible, as blood glucose tends to be more stable earlier in the day.

• Eat normally and take your diabetes medication as prescribed, unless your clinical team advises otherwise.

• Bring your blood glucose monitoring equipment and fast-acting carbohydrate (such as glucose tablets or a sugary drink) to the appointment.

• Inform your dentist of any recent changes to your diabetes management, as these may affect the timing or approach to your treatment.

If you are on insulin or certain oral medications, your team may provide specific pre-operative instructions — always follow their individual advice.

Monitoring HbA1c and Long-Term Implant Care for Diabetic Patients

Diabetic patients should have HbA1c checked every three to six months and attend dental hygiene appointments at risk-based intervals, typically every three to six months, to monitor peri-implant tissue health.

Successful implant placement is not the end of the journey — for patients with diabetes, ongoing monitoring of both glycaemic control and implant health is essential to ensure long-term success. Dental implants require lifelong maintenance, and this is particularly important for diabetic patients who face a higher background risk of peri-implant complications.

In terms of glycaemic monitoring, NICE (NG28) recommends that most people with type 2 diabetes have their HbA1c checked every three to six months until stable, and then every six months thereafter. Maintaining HbA1c within the target range not only supports implant longevity but also reduces the risk of systemic complications associated with poorly controlled diabetes.

For implant-specific aftercare, diabetic patients should:

• Attend regular dental hygiene appointments at intervals determined by their individual risk profile — typically every three to six months, though this may be adjusted based on factors such as oral hygiene, peri-implant tissue health, and glycaemic control — to allow professional cleaning around the implant and early detection of peri-implantitis. BSP/EFP guidance on supportive periodontal and implant care provides a framework for these risk-based recall intervals.

• Maintain meticulous home oral hygiene, including interdental brushing and, where appropriate, use of an antibacterial mouthwash as directed by their dentist.

• Report any signs of implant problems promptly, including swelling, bleeding, pain, or loosening around the implant site, as these may indicate early peri-implant infection requiring prompt treatment.

• Inform their dentist of any significant changes in their diabetes management or overall health, as these may affect implant stability.

If you experience a problem that you believe may be related to your dental implant as a medical device, or a side effect from any medicine used during your treatment, this can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

With well-controlled HbA1c levels and a committed approach to oral hygiene and dental follow-up, many patients with diabetes achieve excellent long-term implant outcomes. The key is consistent collaboration between the patient, their GP or diabetes team, and their dental care provider throughout the entire implant journey.

Frequently Asked Questions